Efficacy and safety of trabectedin for patients with unresectable and ...

Initial trabectedin at 1.2 mg/m 2 has clinically meaningful benefits for patients with L-sarcoma and certain histological subtypes of TRS.

This study retrospectively investigated its efficacy and safety through postmarketing surveillance of trabectedin in patients with unresectable and relapsed ...

Efficacy and safety of trabectedin for patients with unresectable and ...

Although initial trabectedin (1.2 mg/m2) is safe and effective for patients with translocation-related sarcoma (TRS) in Japan, its efficacy in ...

Efficacy and Safety of Trabectedin in Patients With Advanced or ...

To evaluate the safety and efficacy of trabectedin in a phase II, open-label, multicenter, randomized study in adult patients with unresectable/metastatic ...

Efficacy and Safety of Trabectedin or Dacarbazine for Metastatic ...

Trabectedin demonstrates superior disease control versus conventional dacarbazine in patients who have advanced liposarcoma and leiomyosarcoma after they ...

Safety and efficacy of trabectedin when administered in the inpatient ...

The majority of patients randomized to trabectedin in the ET743‐SAR‐3007 trial have received the drug in the outpatient setting. The results of ...

Efficacy and safety of trabectedin in metastatic uterine leiomyosarcoma

More patients receiving trabectedin in 1st-line of advanced disease achieved CR (16.7%) and PR (50.0%) than those in ≥ 2nd line/s (0.0% and 20.0%), whereas the ...

Effectiveness and Safety of Trabectedin and Radiotherapy for ...

Overall, 9 of 41 patients (22%) achieved a partial response with neoadjuvant treatment with trabectedin and RT, with 5 of 39 patients (13%) ...

Efficacy and safety of trabectedin in patients with advanced or ...

0418). Median overall survival (n = 235 events) was 13.9 months versus 11.8 months (HR, 0.843; 95% CI, 0.653 to 1.090; P = .1920). Although ...

FDA Approval Summary: Trabectedin for Unresectable or Metastatic ...

In 2012, the FDA approved pazopanib for patients with advanced STS who have received prior chemotherapy, but efficacy has not been demonstrated for patients ...

Clinical outcomes and safety with trabectedin therapy in patients ...

L-sarcoma patients exhibited longer, OS compared with other histologies [16.2 months (95% confidence interval (CI) 14.1–19.5) versus 8.4 months (95% CI 7.1–10.7)] ...

Real-World Experience of Efficacy and Safety of Trabectedin in ...

Among the 113 patients analyzed for efficacy, the median progression-free survival was 3.0 months (95% CI: 2.3–4.8), with an overall survival of ...

Efficacy and safety of trabectedin in patients with advanced or ...

PURPOSE To evaluate the safety and efficacy of trabectedin in a phase II, open-label, multicenter, randomized study in adult patients with unresectable ...

Trabectedin in Unresectable or Metastatic Liposarcoma or ...

On October 23, 2015, trabectedin (Yondelis) was approved for the treatment of patients with unresectable or metastatic liposarcoma or ...

Assessment of Safety and Efficacy of Combined Trabectedin and ...

Our prospective trial resulted in an ORR of 72%, whereas the RECIST-based ORR with trabectedin alone in patients with advanced STS is below 10%.

A randomized phase III trial comparing trabectedin to best ...

In the BSC arm, patients could not receive antitumor therapy but only treatments to relieve symptoms induced by primary disease and to improve ...

Trabectedin for inoperable or recurrent soft tissue sarcoma in adult ...

Trabectedin has shown efficacy as salvage chemotherapy in patients with advanced STS in three phase II trials [12–14], chemotherapy-naive ...

Trabectedin in patients with advanced soft tissue sarcoma

The results of this real-life study demonstrate that treatment with trabectedin of patients with STS yielded comparable or improved efficacy outcomes.

Safety Profile - YONDELIS®

YONDELIS® (trabectedin) is indicated for the treatment of patients with unresectable or metastatic liposarcoma or leiomyosarcoma who received a prior ...

Safety and Efficacy of the Combination Lurbinectedin plus ...

Lurbinectedin is related to trabectedin, an agent approved in Europe (second line or greater, adult patients with advanced STS) and in the ...